Medinice

Medinice Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Medinice (ICE.WA) as of Nov 2, 2026 is 0.79. In the previous year, Net Debt to Free Cash Flow Ratio was 2.40 — a change of -66.96% (lower).

Net Debt/FCF

0.79

YoY

-66.96%

Last updated:

Net Debt to Free Cash Flow Ratio of Medinice is 2025 0.79 . Net Debt to Free Cash Flow Ratio of Medinice was 2024 2.40 . It decreases by -66.96% lower compared to the previous year.

The Medinice Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
1.75 PLN
Jan 1, 2019
0.83 PLN
Jan 1, 2020
1.80 PLN
Jan 1, 2021
5.18 PLN
Jan 1, 2022
3.27 PLN
Jan 1, 2023
0.99 PLN
Jan 1, 2024
2.40 PLN
Jan 1, 2025
0.79 PLN
The Medinice Net Debt/FCF history
YEARNet Debt/FCFYoY
0.79-66.96%
2.40+142.50%
0.99-69.72%
3.27-36.85%
5.18+187.86%
1.80+117.20%
0.83-52.82%
1.75+76.30%
1.00-403.06%
-0.33—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinice Stock analysis

What does Medinice do? Medinice SA generates revenue through the commercialization of medical device solutions, primarily focusing on cardiological and cardiosurgical products. The company's portfolio includes CathAIO, Cryoapplicator, Med-IConsole, Minimax, and Pacepress, which are sold globally via licensing agreements. These products target healthcare providers and medical device manufacturers seeking minimally invasive cardiology solutions. The firm collaborates with research centers in Poland and Europe to develop and commercialize inventions from its co-founders and acquired projects, emphasizing safe and minimally invasive medical technologies. Medinice SA's business model revolves around licensing its proprietary technologies to international partners for the production of medical devices. The company leverages its global potential projects to secure worldwide distribution agreements, ensuring revenue streams from multiple markets. By specializing in cardiology and cardio surgery, Medinice SA positions itself as a provider of innovative solutions for healthcare systems seeking advanced, minimally invasive procedures. The firm's revenue is derived from licensing fees and sales of its medical device solutions, with a focus on cardiological and cardiosurgical applications. Its products, such as CathAIO and Cryoapplicator, are designed to meet global demand for safe and minimally invasive treatments. Medinice SA's strategy involves partnering with research centers in Poland and Europe to enhance its portfolio, ensuring continuous innovation and market relevance in the medical device sector. Medinice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinice stock

Net Debt to Free Cash Flow Ratio of Medinice is 0.79 in 2025.

Net Debt to Free Cash Flow Ratio of Medinice changed from 2.40 to 0.79, representing a -66.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Medinice since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Medinice with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Medinice

All Key Metrics — Medinice